Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

282
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
282
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.2K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

308
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
308
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

527
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
527
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

285
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
285
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.5K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic regulation of visual acuity.

Science advances·2025
Same author

Double-Hit Mimics of Idiopathic Intracranial Hypertension.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2023
Same author

Apraxia of lid opening in multiple sclerosis.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2022
Same author

Sphenoid Sinusitis-Associated Optic Neuropathy: A Forgotten Disease.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2022
Same author

Posterior Ischemic Optic Neuropathy Following Recurrent COVID-19 in Prior Bilateral Sequential Nonarteritic Anterior Ischemic Optic Neuropathy.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2022
Same author

Optic nerve sheath diameter and spaceflight: defining shortcomings and future directions.

NPJ microgravity·2022

Related Experiment Video

Updated: Nov 11, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.4K

Corticosteroid Usage in Giant Cell Arteritis.

Amritha Kanakamedala1, Mariam Hussain2, Ashwini Kini3

  • 1School of Medicine, Baylor University College of Medicine, Houston, Texas, USA.

Neuro-Ophthalmology (Aeolus Press)
|March 25, 2021
PubMed
Summary
This summary is machine-generated.

Giant cell arteritis (GCA) treatment varies. High-dose intravenous corticosteroids are often used for GCA with visual loss, while oral corticosteroids are preferred for GCA without visual loss, though consensus is incomplete.

Keywords:
Giant Cell Arteritiscorticosteroiddosagevasculitisvision Loss

More Related Videos

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.7K
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

525

Related Experiment Videos

Last Updated: Nov 11, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.4K
Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.7K
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

525

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Neurology

Background:

  • Giant cell arteritis (GCA) is a vasculitis that can lead to irreversible vision loss.
  • Corticosteroids are the primary treatment for GCA to prevent visual impairment.
  • Optimal corticosteroid regimen (type, dose, route, duration) for GCA is debated.

Purpose of the Study:

  • To survey neuro-ophthalmologists regarding current corticosteroid prescribing practices for GCA.
  • To identify common dosages and routes of corticosteroid administration for GCA with and without visual loss.

Main Methods:

  • A survey was distributed to neuro-ophthalmologists.
  • The survey queried preferred corticosteroid treatments for GCA patients presenting with or without acute visual loss.

Main Results:

  • For GCA with acute visual loss, 73% of neuro-ophthalmologists favored 500-1000 mg IV methylprednisolone.
  • For GCA without acute visual loss, 75% preferred 1.0-1.5 mg/kg oral prednisone.
  • Practices showed a majority consensus but not complete agreement on corticosteroid regimens.

Conclusions:

  • Current practices align with established recommendations: high-dose IV corticosteroids for GCA with visual loss and lower-dose oral regimens for GCA without visual loss.
  • A significant portion of neuro-ophthalmologists utilize IV or oral corticosteroid options for GCA, indicating variability in treatment approaches.